Else Nutrition Holdings Inc. logo (CNW Group/Else Nutrition Holdings Inc.)
Else Nutrition Holdings Inc. has announced a significant development in its pursuit of bringing its plant-based infant formula to the U.S. market. On March 10, 2026, the U.S. Food and Drug Administration (FDA) confirmed that it has listed the Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active area of focus within its regulatory agenda for food products. This advancement is expected to provide a clearer pathway for regulatory approval of novel infant formulas, particularly those based on plant-derived ingredients.
The FDA’s new guidelines represent a crucial step forward for companies like Else, which specialize in whole-food, plant-based nutrition for early childhood. Historically, the existing standards for assessing protein quality in infant formulas have been outdated, leading to uncertainty for brands developing innovative formulations. By advancing the PER guidance, the FDA aims to clarify the expectations surrounding study design and protein quality validation. This clarity is anticipated to alleviate regulatory risks that have hindered Else’s progress in the U.S. market.
Streamlining Infant Formula Regulations
The U.S. infant formula sector is one of the largest globally but has faced criticism for its limited variety of protein sources. Lawmakers and federal agencies have increasingly called for an expansion of consumer choices, particularly in the realm of non-dairy and plant-based options. Else Nutrition emphasized this need in a statement released in June 2025, advocating for the diversification of the U.S. infant formula market.
The FDA’s focus on modernizing the PER guidelines aligns with broader federal initiatives such as Operation Stork Speed, which seeks to update regulatory frameworks and nutrient standards for infant formulas for the first time since 1998. This initiative aims to enhance transparency and streamline the approval process for new products, a move that is expected to significantly benefit companies introducing innovative formulations.
For Else Nutrition, the updated PER methodology is particularly advantageous. Most competitors predominantly rely on conventional dairy or soy proteins. The new guidelines will allow Else to demonstrate the quality of its plant-based protein sources on a more equitable regulatory footing, ultimately bolstering its position within the market.
Strategic Advantages for Else Nutrition
As regulatory modernization continues, Else Nutrition is poised to capitalize on multiple industry trends. There is a growing demand for clean-label and plant-based nutrition, alongside federal efforts to foster competition and innovation in the U.S. formula market. With increased regulatory transparency, the pathway for new product approvals becomes clearer, enhancing Else’s capability to enter the lucrative U.S. infant formula sector.
Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition, expressed optimism regarding these recent developments. “The FDA’s progress on PER guidance is a meaningful inflection point for Else Nutrition,” Yitzhak stated. “As clarity increases around the scientific and procedural standards required for novel infant formulas, our regulatory roadmap becomes sharper, more predictable, and increasingly aligned with federal efforts to modernize the U.S. formula market.”
Else Nutrition’s commitment to innovation in plant-based nutrition not only strengthens its market position but also appeals to long-term institutional investors, ESG-focused funds, and growth investors. The alignment between its product strategy and evolving regulatory priorities reinforces the company’s potential for success in the expanding infant formula market.
For further information about Else Nutrition’s offerings and revolutionary approach to nutrition, interested parties can visit their website at www.elsenutrition.com.
